Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 23281876)

1.

The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia.

Chue P, Malla A, Bouchard RH, Lessard S, Ganesan S, Stip E, Johnson S, Chen E, Ahn YM, Kim YS, Robinson G, Schweikert C, Gendron A, Eriksson H; SPECTRUM XR Study Group.

Curr Med Res Opin. 2013 Mar;29(3):227-39. doi: 10.1185/03007995.2012.762903. Epub 2013 Jan 22.

PMID:
23281876
2.

Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia.

Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D; Study 147 Investigators.

Curr Med Res Opin. 2008 Jan;24(1):21-32.

PMID:
18021496
3.

Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.

Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D; Study 132 Investigators.

J Clin Psychiatry. 2007 Jun;68(6):832-42.

PMID:
17592906
5.

Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.

Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D.

Clin Ther. 2011 Nov;33(11):1643-58. doi: 10.1016/j.clinthera.2011.10.002. Epub 2011 Nov 4.

PMID:
22054797
6.
7.

[Administration of once-daily extended release quetiapine in schizophrenic disorders].

Bartkó G.

Neuropsychopharmacol Hung. 2007 Dec;9(4):189-95. Hungarian.

8.

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia.

Järbrink K, Kreif N, Benedict A, Locklear J.

Curr Med Res Opin. 2009 Mar;25(3):709-16. doi: 10.1185/03007990902738810 .

PMID:
19196221
9.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
10.

Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.

Möller HJ, Johnson S, Mateva T, Brecher M, Svensson O, Miller F, Meulien D; Study 146 Investigators.

Int Clin Psychopharmacol. 2008 Mar;23(2):95-105. doi: 10.1097/YIC.0b013e3282f2d42c.

PMID:
18301124
11.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.

El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H.

Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.

PMID:
20175941
12.

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H.

Int J Neuropsychopharmacol. 2010 Apr;13(3):305-20. doi: 10.1017/S1461145709990423. Epub 2009 Aug 20.

PMID:
19691907
13.

Quetiapine: a review of its use in the management of bipolar depression.

Sanford M, Keating GM.

CNS Drugs. 2012 May 1;26(5):435-60. doi: 10.2165/11203840-000000000-00000. Review.

PMID:
22519923
14.

Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.

Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S.

J Child Adolesc Psychopharmacol. 2012 Oct;22(5):327-42. doi: 10.1089/cap.2011.0092.

PMID:
23083020
15.

Quetiapine extended release: in schizophrenia.

Baldwin CM, Scott LJ.

CNS Drugs. 2009;23(3):261-9. doi: 10.2165/00023210-200923030-00007. Review.

PMID:
19320534
16.

Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia.

Lee JG, Lee JI, Kim YT, Kim CE, Kim CY, Yoon JS, Yoo SY, Kim YH.

Hum Psychopharmacol. 2012 Jul;27(4):403-10. doi: 10.1002/hup.2241. Epub 2012 Jul 3.

PMID:
22753400
17.
18.

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.

Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group.

CNS Spectr. 2009 Jun;14(6):299-313.

PMID:
19668121
19.

Long-Term use of quetiapine in elderly patients with psychotic disorders.

Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW.

Clin Ther. 2000 Sep;22(9):1068-84.

PMID:
11048905
20.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk